Atlas Trials

Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Clinical trial NCT05808582 · UNKNOWN

Trial details

NCT number
NCT05808582
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hormone Receptor-positive Advanced Breast Cancer
Start date
2023-05-01
Primary completion
2023-09-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.